Real-world first-line serplulimab therapy for advanced esophageal cancer: effectiveness, safety, and clinical implications
This multicenter, observational cohort study aimed to evaluate the real‑world outcomes, and address evidence gaps in broader patient populations.
The phase III ASTRUM-007 trial demonstrated significant clinical benefit in patients with PD‑L1‑positive esophageal squamous cell carcinoma (ESCC) treated with first‑line serplulimab plus chemotherapy. This multicenter, observational cohort study aimed to evaluate the real‑world outcomes, and address evidence gaps in broader patient populations.
The study provides real‑world evidence for the effectiveness and safety of serplulimab‑based regimens as first‑line therapy in a diverse population of patients with advanced esophageal cancer.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Advances in targeted therapy for esophageal cancer
- A review of esophageal cancer research: emerging trends, progress and perspectives
- An esophageal cancer clinical trial - ES3
- Case Report: Small bowel metastasis from esophageal squamous cell carcinoma: a case series and systematic review of clinical characteristics, tropism, and survival outcomes
- Current landscape of immunotherapy in esophageal cancer: a literature review